A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
Clinical trial NCT04302103 · COMPLETED
Trial details
- NCT number
- NCT04302103
- Sponsor
- RemeGen Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-07
- Primary completion
- 2022-01-14
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.